Considerations for the Development and Manufacturing of Biosimilars [Presentation]

The Emerging Landscape of GLP-1 RA Therapies Across Conditions

Multidrug combinations may counteract the role of cytokines in drug resistance, a new review article explains.

October 14th 2025

Low Trial Enrollment, Racial Disparities Limit Breast Cancer Treatment Innovation

The founder and President of Phesi addresses the need for streamlining clinical trial data as GLP-1 RA therapies are being used to treat multiple diseases.

Listen

AI may help optimize breast cancer clinical trial enrollment rates and trial design. | Image Credit: @Pixel-Shot-AdobeStock.jpeg

Follow the Science: Bridging the Biosimilar Gap With Dr Hillel Cohen

Artificial intelligence models may advance clinical trial design and enrollment to improve trial success and patient outcomes.

The Center for Biosimilars podcast banner

July 29th 2025

Revumenib Granted FDA Approval for R/R NPM1-Mutated AML

Listen

FDA Approval in white letters on blue background with a green checkmark | Image credit: maggie - sora.chatgpt.com

Rising Global Temperatures Increase Heat-Related Mortality in Older Patients With Heart Failure

The FDA approved revumenib for relapsed/refractory (R/R) acute myeloid leukemia, offering a new targeted therapy option for patients with NPM1 mutations.

Rising temperatures increase the risk of cardiovascular death in older patients with heart failure. | Image Credit: @24Novembers-AdobeStock.jpeg

Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear

Increases in global temperatures may exacerbate cardiovascular mortality risk in older patients with heart failure.

Related Content

October 26th 2025

The Emerging Landscape of GLP-1 RA Therapies Across Conditions

Multidrug combinations may counteract the role of cytokines in drug resistance, a new review article explains.

October 14th 2025

Low Trial Enrollment, Racial Disparities Limit Breast Cancer Treatment Innovation

The founder and President of Phesi addresses the need for streamlining clinical trial data as GLP-1 RA therapies are being used to treat multiple diseases.

Listen

Follow the Science: Bridging the Biosimilar Gap With Dr Hillel Cohen

Artificial intelligence models may advance clinical trial design and enrollment to improve trial success and patient outcomes.

July 29th 2025

Revumenib Granted FDA Approval for R/R NPM1-Mutated AML

Listen

Rising Global Temperatures Increase Heat-Related Mortality in Older Patients With Heart Failure

The FDA approved revumenib for relapsed/refractory (R/R) acute myeloid leukemia, offering a new targeted therapy option for patients with NPM1 mutations.